What happened
ST嘉应 told investors that its loss in the first half of the year was primarily caused by a decline in sales revenue for some of its pharmaceutical products, which were affected by the national centralized procurement policy.
The company made the remarks during an investor relations event, according to a report from Southern Finance and Economics.
Why it matters
The statement highlights how national volume-based procurement can pressure drugmakers' revenues when their products are included in centralized purchasing programs.
For investors, the explanation ties the company's financial performance directly to a policy factor rather than operational issues, which may shape expectations for future quarters.
Key facts
ST嘉应 reported a loss for the first half of the year.
The company said the loss was mainly due to some drugs being affected by the national centralized procurement policy.
Sales revenue for those drugs declined.
What to watch next
Whether ST嘉应 provides further details on which products were affected and how it plans to mitigate the impact.
Any updates on the company's performance in subsequent periods as the procurement policy continues to affect sales.